119045-87-3

Upstream product

• 25413-27-8 3-(4-methoxy-phenyl)propionamide 
• 55-81-2 4-Methoxyphenethylamine 
• 37567-58-1 2-(4-hydroxyphenyl)-1-nitroethane 
• 51-67-2 tyrosamine 
• 75-07-0 acetaldehyde 
• 175287-92-0 N-(4-methoxy-phenethyl)-benzenesulfonamide 
• 75-03-6 ethyl iodide 

Downstream Products

• 1354828-51-5 tert-butyl 2-(4-(4-(2-(ethylamino)ethyl)phenoxy)phenyl)azocarboxylate 

Relevant academic research and scientific papers

Direct Reductive N-Functionalization of Aliphatic Nitro Compounds

The first general protocol for the direct reductive N-functionalization of aliphatic nitro compounds is presented. The nitro group is partially reduced to a nitrenoid, with a mild and readily available combination of B2pin2 and zinc organyls. Thereby, the formation of an unstable nitroso intermediate is avoided, which has so far severely limited reductive transformations of aliphatic nitro compounds. The reaction is concluded by an electrophilic amination of zinc organyls.

SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE

The invention provides compounds of formula I and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS.